Advances in the Study of Chemokine-like Factor Superfamily Members in Tumors.
10.3779/j.issn.1009-3419.2023.106.01
- Author:
Gang XIE
1
;
Jing CHENG
1
;
Junping ZHANG
1
Author Information
1. Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
- Publication Type:Journal Article
- Keywords:
Biomarker;
CKLF;
CMTM;
Chemokine-like factor;
Tumor
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
Lung Neoplasms;
MARVEL Domain-Containing Proteins/metabolism*;
Cell Proliferation;
Chemokines/metabolism*;
Tumor Microenvironment
- From:
Chinese Journal of Lung Cancer
2023;26(1):46-51
- CountryChina
- Language:Chinese
-
Abstract:
Chemokine-like factor-like MARVEL transmembrane domain containing member/chemokine-like factor superfamily member (CMTM/CKLFSF) including CKLF and CMTM1-CMTM8 are a new family of proteins linking chemokines and transmembrane superfamilies. CMTM not only have broad chemotactic activities, but also associate with hematopoietic system, immune system, and tumor development and metastasis closely. CMTM proteins are involved in key biological processes of cancer development, which include activation and recycling of growth factor receptors, cell proliferation and metastasis, and regulation of the tumor immune microenvironment. This is a new focus of research on the relationship between CMTM and tumors, because CMTM4/CMTM6 can be considered as a regulator for programmed cell death ligand 1 (PD-L1). This paper reviews the role of CMTM family members on cancer, especially in tumor growth, metastasis and immune escape, summarize the latest findings on the relationship between CMTM and non-small cell lung cancer, and explores the potential clinical value of CMTM as a novel drug target or biomarker.
.
